Physician profile
Scott Eller
NPI 1467418871
$17,366.60
in general payments reported to CMS, 2019-2025
63 companies · $2,768 in 2025
The $2,768 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,070 · 2020: $1,860 · 2021: $2,238 · 2022: $2,910 · 2023: $2,822 · 2024: $2,699 · 2025: $2,768.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,278 · Education: $10.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,278.22 |
| Education | $10.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,146.13 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,757.67 | 2019-2025 | |
| Pfizer INC. | $1,142.47 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $878.98 | 2019-2025 | Jardiance, Synjardy, Ofev |
| Amgen INC. | $872.40 | 2019-2025 | Repatha, Otezla, Otezla |
| Otsuka America Pharmaceutical, INC. | $864.46 | 2020-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $858.15 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $828.56 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $703.51 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $551.48 | 2019-2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $538.07 | 2019-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $430.83 | 2019-2023 | Belsomra, Verquvo, Steglatro |
| Sanofi-Aventis U.S. LLC | $420.05 | 2019-2025 | |
| Antares Pharma, INC. | $406.40 | 2020-2025 | Xyosted, Nocdurna, Tlando |
| Lundbeck LLC | $369.77 | 2021-2025 | Vyepti, Rexulti |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Eller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.